niclosamide
Selected indexed studies
- Niclosamide-A promising treatment for COVID-19. (Br J Pharmacol, 2022) [PMID:35348204]
- Niclosamide: A career builder. (J Control Release, 2024) [PMID:37544514]
- Niclosamide: Beyond an antihelminthic drug. (Cell Signal, 2018) [PMID:28389414]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Niclosamide-A promising treatment for COVID-19. (2022) pubmed
- Niclosamide: A career builder. (2024) pubmed
- Niclosamide: Beyond an antihelminthic drug. (2018) pubmed
- Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases. (2022) pubmed
- Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning. (2024) pubmed
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics. (2025) pubmed
- Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. (2019) pubmed
- Niclosamide potentiates TMEM16A and induces vasoconstriction. (2024) pubmed
- Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. (2022) pubmed
- Repurposing Niclosamide as a plausible neurotherapeutic in autism spectrum disorders, targeting mitochondrial dysfunction: a strong hypothesis. (2024) pubmed